PARP inhibition promotes endothelial-like traits in melanoma cells and modulates pericyte coverage dynamics during vasculogenic mimicry.
Mónica Fernández-CortésDaniel Delgado-BellidoEloísa Bermúdez-JiménezJesús M ParamioFrancisco O'ValleStefan VinckierPeter CarmelietAngel Garcia-DiazFrancisco Javier OliverPublished in: The Journal of pathology (2022)
Vasculogenic mimicry (VM) describes the ability of highly aggressive tumor cells to develop pseudovascular structures without the participation of endothelial cells. PARP1 is implicated in the activation of hypoxia-inducible factors, which are crucial in tumor neovascularization. We have explored the role of hypoxia and PARP inhibition in VM. In uveal melanoma xenografts, the PARP inhibitor olaparib improved in vivo pericyte coverage specifically of VM channels. This was concomitant with reduced metastasis in olaparib-treated VM + tumors. PARP inhibition and hypoxia modulated melanoma tube formation in vitro, inducing a more sparse and regular tubular architecture. Whole-transcriptome profiling revealed that olaparib treatment under hypoxic conditions modulated the expression of genes implicated in vasculogenesis during tube formation, enhancing the endothelial-like phenotype of VM + uveal melanoma cells. PARP inhibition, especially during hypoxia, upregulated PDGFβ, which is essential for pericyte recruitment. Our study indicates that PARP inhibitors may enhance the endothelial characteristics of VM + cells, modulate pericyte coverage and reduce metastatic spread in VM + melanoma. This article is protected by copyright. All rights reserved.
Keyphrases
- endothelial cells
- dna damage
- dna repair
- blood brain barrier
- high glucose
- vascular endothelial growth factor
- single cell
- genome wide
- squamous cell carcinoma
- poor prognosis
- gene expression
- induced apoptosis
- healthcare
- affordable care act
- signaling pathway
- smooth muscle
- rna seq
- angiotensin ii
- diabetic retinopathy
- newly diagnosed
- long non coding rna
- replacement therapy